Anticoagulants in cancer.

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Cancer patients have a high risk of venous thromboembolism (VTE), leading to significant morbidity and mortality.
• Anticoagulant use for VTE in cancer patients involves complex risk-benefit considerations, especially in non-surgical and outpatient settings.

Purpose of the Study:

• To review current evidence on anticoagulant use for VTE treatment and prevention in cancer patients.
• To identify gaps in knowledge and areas requiring further clinical investigation.

Main Methods:

• Narrative review of existing literature on anticoagulants for VTE in cancer patients.
• Analysis of evidence regarding perioperative prophylaxis, treatment of acute VTE, and prophylactic use in non-surgical settings.

Main Results:

• Perioperative anticoagulant prophylaxis is well-established.
• Low molecular weight heparin (LMWH) may offer a survival benefit in some cancer patients without VTE, but specific populations need definition.
• Guidelines recommend LMWH for acute VTE, but optimal duration and practical use are unclear.

Conclusions:

• While LMWH is a preferred treatment for acute VTE in cancer patients, optimal duration and real-world application need clarification.
• Novel oral anticoagulants require further study for efficacy and safety in this population.
• High-quality clinical trials are essential to address remaining questions regarding VTE management in cancer patients.